Research analysts at StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX – Get Free Report) in a report issued on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.
BioLineRx Stock Performance
BLRX stock opened at $0.40 on Wednesday. The company has a market capitalization of $31.98 million, a P/E ratio of -0.53 and a beta of 1.46. The company has a 50-day simple moving average of $0.59 and a 200 day simple moving average of $0.65. BioLineRx has a fifty-two week low of $0.39 and a fifty-two week high of $1.93. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34.
BioLineRx (NASDAQ:BLRX – Get Free Report) last posted its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09. The company had revenue of $5.39 million during the quarter, compared to analyst estimates of $3.93 million. Sell-side analysts predict that BioLineRx will post -0.25 earnings per share for the current fiscal year.
Institutional Investors Weigh In On BioLineRx
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Further Reading
- Five stocks we like better than BioLineRx
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Why Are These Companies Considered Blue Chips?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Invest in Blue Chip Stocks
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.